<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03761368</url>
  </required_header>
  <id_info>
    <org_study_id>RNN/219/13/KE</org_study_id>
    <nct_id>NCT03761368</nct_id>
  </id_info>
  <brief_title>Remote Ischemic Preconditioning and Contrast Induced - Acute Kidney Injury in Patients Undergoing Elective PCI</brief_title>
  <official_title>Remote Ischemic Preconditioning and Contrast Induced - Acute Kidney Injury in Patients Undergoing Elective Percutaneous Coronary Intervention - Randomised Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Universtity of Lodz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical Universtity of Lodz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized, sham-controlled clinical study was conducted to assess whether RIPC
      reduces the incidence of CI-AKI measured standard way of using SCr concentration but also
      with the use of serum NGAL as a new potential biomarker of kidney injury. Furthermore, the
      aim of investigation was to analyse the safety and clinical outcomes of RIPC after elective
      coronary angiography (CA) followed by percutaneous coronary intervention (PCI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nowadays CI-AKI is defined according to serum creatinine concentration (SCr) as any of the
      following: (1) an absolute rise of ≥ 0.5 mg/dL(44 µmol/L) and/or (2) a relative increase of
      25% in serum creatinine compared to baseline within 48 to 72 hours after contrast
      administration. In the last decades, several novel biomarkers of AKI have been studied
      including neutrophil gelatinase-associated lipocalin (NGAL). Furthermore, remote ischemic
      preconditioning (RIPC) turned out to be one of the most promising and intriguing
      non-pharmacological strategy. This simple procedure consisting of brief, non-lethal episodes
      of ischemia and reperfusion applied in one tissue or organ protects remote tissues or organs
      from subsequent injury.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2015</start_date>
  <completion_date type="Actual">June 30, 2018</completion_date>
  <primary_completion_date type="Actual">June 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>After admission to the Department, patients were randomly assigned in 1:1 ratio to either control group or RIPC - group by means of a computerized randomization table.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>Blinded investigator, not involved in either CA or randomization procedure, performed assignment intervention.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>the incidence of Contrast Induced-Acute Kidney Injury</measure>
    <time_frame>48 to 72 hours after contrast exposure</time_frame>
    <description>absolute rise of ≥ 0.5 mg/dL (44 µmol/L) and/or a relative increase of 25% in serum creatinine compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with need of renal replacement therapy</measure>
    <time_frame>up to 7 days after contrast exposure</time_frame>
    <description>qualification for RRT according to standard clinical criteria (level of serum creatinine, serum urea concentration, electrolytes levels (sodium, potassium, chlorides), hydration management)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants who presented cardiogenic shock</measure>
    <time_frame>up to 7 days after contrast exposure</time_frame>
    <description>sustained hypotension (systolic blood pressure &lt; 90 mm Hg for ≥30 min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants who died</measure>
    <time_frame>up to one month after contrast exposure</time_frame>
    <description>death of any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Remote Ischemic Preconditioning</condition>
  <condition>Contrast Induced - Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>RIPC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The RIPC group underwent Remote Ischemic Preconditioning.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients from control group had sham Remote Ischemic Preconditioning.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Remote Ischemic Preconditioning</intervention_name>
    <description>four cycles of 5-min inflation to 200 mmHg followed by 5-min deflation of left upper - arm cuff</description>
    <arm_group_label>RIPC group</arm_group_label>
    <other_name>RIPC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham Remote Ischemic Preconditioning</intervention_name>
    <description>deflated cuff placed on the left arm for 40 min</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Sham RIPC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged over 18 years

          -  patients with stable angina pectoris

          -  patients admitted to Intensive Cardiac Therapy Clinic Medical University of Lodz with
             intention of elective CA with follow-up PCI.

        Exclusion Criteria:

          -  history of severe injuries up to 2 months before intervention

          -  history of surgeries up to 2 months before intervention

          -  history of cancer,

          -  acute inflammation during hospitalization

          -  chronic autoimmunologic diseases

          -  patients needing hemodialysis

          -  chronic kidney disease in stage 4 or 5 (eGFR&lt;30 ml/min/1,73m2)

          -  peripheral vascular disease affecting upper limbs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marzenna Zielinska, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of Lodz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Intensive Cardiac Therapy Clinic</name>
      <address>
        <city>Lodz</city>
        <zip>92-213</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 29, 2018</study_first_submitted>
  <study_first_submitted_qc>November 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2018</study_first_posted>
  <last_update_submitted>November 30, 2018</last_update_submitted>
  <last_update_submitted_qc>November 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical Universtity of Lodz</investigator_affiliation>
    <investigator_full_name>Karolina Stokfisz</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>remote ischemic preconditioning</keyword>
  <keyword>contrast induced-acute kidney injury</keyword>
  <keyword>neutrophil gelatinase-associated lipocalin</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>3 years after the end of the study</ipd_time_frame>
    <ipd_access_criteria>on reasonable request</ipd_access_criteria>
  </patient_data>
  <pending_results>
    <submitted>June 12, 2020</submitted>
    <returned>July 1, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

